UNIVERSITI TEKNOLOGI MARA

BLOOD-BASED BIOMARKERS FOR EARLY DETECTION OF ALZHEIMER'S DISEASE

MAISARAH BINTI AHMAD

Dissertation submitted in partial fulfillment of the requirement for the degree of Bachelor of Pharmacy (Hons.)

Faculty of Pharmacy

ACKNOWLEDGEMENT

Firstly, deepest gratitude and praises to Allah, for giving me the ability to finish this final year project with success.

I would like to express gratitude to my parents and family for their moral support to me. Their moral support gave me such strength to finish this final year project.

I would like to record my appreciation to my supervisor, Professor Dato' Dr. Abu Bakar Abdul Majeed for his support and recommendations while doing the final year project.

I would also like to state my gratitude to my co-supervisor, Dr.Ainon Zahariah Samsudin for her willingness to help me during laboratory work.

Not to forget, deepest appreciation also goes to Brain Laboratory staffs for their help and information while using the equipment for my laboratory work.

TABLE OF CONTENTS

			Page
TITI	LE PAGE		
APPROVAL			ii
ACKNOWLEDGEMENT			iii
TABLE OF CONTENTS			iv
LIST OF EQUATIONS			vii
LIST OF FIGURES			viii
LIST OF TABLES			X
LIST OF ABBREVIATIONS			xi
ABSTRACT			xii
CHAPTER ONE		INTRODUCTION	
1.1	Background of Study		1
1.2	Problem Statement		2
1.3	Objective of Study		5
1 4	Significance of Study		6

ABSTRACT

Alzheimer's disease (AD) is one of the most common forms of dementia. Finding a biomarker for early detection of AD based on blood source has been a goal of researchers for many years. Studies have proven about 80% of human gene expression are found in the blood. We performed quantitative real-time polymerase chain reaction (RT-PCR) to determine the relative expression of gene in AD compared to healthy subjects by using mathematical model called Pfaffl method. Based on the Pfaffl method, we found that the relative expression of mitogenactivated protein kinase (MAP2K1) was higher relative to healthy subjects based on fold change ratio after normalization with reference gene, beta-actin (β -actin). This study provides evidence that blood can be a source of biomarkers for early detection of AD and thus can give an impact in terms of clinical practice, and ultimately may improve the patient's quality of life.

CHAPTER 1

INTRODUCTION

1.1 Background of study

Alzheimer's disease (AD) is one of the most common forms of dementia and the estimated lifetime risk for developing AD is about 20% in women and 10% in men with the age of 65 years old and above (Chouliaras et al., 2010).

It is a chronic neurodegenerative disorder. AD is an age-related, progressive neurodegenerative disease resulting in the loss of cognitive ability necessary for maintaining an independent lifestyle. The trend of increasing age in the world population profile has been accompanied by a steady rise in the prevalence of AD (Kaddurah et al., 2009).

Clinically, AD is characterized by a slow progression loss of cognitive functions and neuropathologically, AD is characterized by the accumulation of misfolded protein namely beta-amyloid (A β) protein in the form of senile plaques together with hyperphosphorylated tau (τ) protein in the form of neurofibrillary tangles (NFT) (Bertram, Lill & Tanzi, 2010).

During the G8 Dementia Summit that was held on December 11, 2013 in London, the tragedy of AD was raised by British Prime Minister, David Cameron. UK Health Secretary Jeremy Hunt had described the condition as a global challenge during the summit. AD contributes to 62% of those living with dementia. Dementia is incurable